Efficacy of the dietary supplement Estrovel in complex therapy for chronic cystitis in perimenopausal women

The paper gives the results of a prospective randomized study based on a follow-up of 49 women aged 46 to 68 years who had chronic cystitis. Group 1 (n = 20) received only etiotropic therapy (monural 3.0 mg once daily and, on the first day, furamag 50 mg thrice for 7 days). Group 2 (n = 29) took additionally estrovel 500 mg twice daily for 2 months. The patients were followed up for 6 months. In Group 2 estrovel-treated patients, there was a considerable microcirculatory improvement in the mucosae of the urinary bladder and vagina and normalization of vaginal acid-base balance (mean pH value 4.±0.3). The supplement Estrovel was found to arrest menopausal symptoms, to provide a long relapse-free period, to resume or improve a sexual life and, eventually, to substantially increase quality of life in these women. No significant side effect of the therapy was recorded in any women.

perimenopause, chronic cystitis, therapy, the supplement estrovel